Bispecific antibody mediated targeting of nido-carboranes to human colon carcinoma cells.
Bispecific antibody mediated targeting of nido-carboranes to human colon carcinoma cells.
复制标题
双特异性抗体介导巢碳硼烷靶向人结肠癌细胞。
DOI：
10.1021/bc960050m
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
Hawthorne,MF
中科院分区：
文献类型：
--
作者：
Primus,FJ;Pak,RH;Richard-Dickson,KJ;Szalai,G;BolenJr,JL;Kane,RR;Hawthorne,MF
硼中子俘获疗法是一种二元形式的癌症治疗方法，如果能够开发出在肿瘤中选择性地增加硼-10浓度的方法，则硼中子俘获疗法具有向肿瘤细胞提供强效细胞毒性辐射的潜力，而对正常组织的附带损伤最小。在这方面，产生了对阴离子硼簇化合物（巢式碳硼烷）和肿瘤相关抗原（癌胚抗原，CEA）具有双重特异性的单克隆抗体。使用该双特异性抗体实现氨基碳硼烷与CEA表达肿瘤细胞的特异性结合。这种双特异性抗体在体内选择性聚集在肿瘤部位的能力也已得到证实，从而表明其在肿瘤中螯合富硼化合物的潜力。
Boron neutron capture therapy, a binary form of cancer treatment, has the potential to deliver potent cytotoxic radiation to tumor cells with minimal collateral damage to normal tissues if methods for the selective accretion of elevated concentrations of boron-10 in tumor can be developed. In this regard, a monoclonal antibody with dual specificity, for both anionic boron cluster compounds (nido-carboranes) and a tumor-associated antigen (carcinoembryonic antigen, CEA), was produced. The specific binding of anido-carborane to CEA-expressing tumor cells was achieved using this bispecific antibody. The ability of this bispecific antibody to concentrate selectively at tumor sitesin vivohas also been demonstrated, thus suggesting its potential for sequestering boron-rich compounds in tumors.